Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform
Walker JL, Schultze A, Tazare J, Tamborska A, Singh B, Donegan K, Stowe J, Morton CE, Hulme WJ, Curtis HJ, Williamson EJ, Mehrkar A, Eggo RM, Rentsch CT, Mathur R, Bacon S, Walker AJ, Davy S, Evans D, Inglesby P, Hickman G, MacKenna B, Tomlinson L, Ca Green A, Fisher L, Cockburn J, Parry J, Hester F, Harper S, Bates C, Evans SJ, Solomon T, Andrews NJ, Douglas IJ, Goldacre B, Smeeth L, McDonald HI. Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform. Vaccine 2022, 40: 4479-4487. PMID: 35715350, PMCID: PMC9170533, DOI: 10.1016/j.vaccine.2022.06.010.Peer-Reviewed Original ResearchMeSH Keywords2019-nCoV Vaccine mRNA-1273Bell PalsyBNT162 VaccineChAdOx1 nCoV-19COVID-19COVID-19 VaccinesEnglandFacial ParalysisGuillain-Barre SyndromeHumansMyelitis, TransverseVaccinationConceptsGuillain-Barré syndromeAcute neurological eventsBell's palsyCOVID-19 vaccinationTransverse myelitisChAdOx1 vaccineOpenSAFELY platformFirst doseNeurological eventsRate of GBSSelf-controlled case series designIncidence rate ratiosPrimary care dataRare adverse eventsSelf-controlled case seriesConditional Poisson regressionCOVID-19 vaccineCase series designBNT162b2 vaccineesChAdOx1 vaccinationVaccine recipientsAdverse eventsHospital admissionCase seriesAbsolute risk